Earnings Calls In Brief
This article was originally published in The Gray Sheet
Executive Summary
Consumers still spending for Allergan aesthetic treatments: Aesthetic product sales pushed Allergan's device revenues ahead 70% in the fourth quarter compared to a year ago, to $216.9 million, or 49% on a pro-forma local currency basis after accounting for acquisitions, the firm reports Jan. 30. Sales of facial dermal fillers, including Juvederm, more than doubled to $61 million while breast implant sales increased 38% to $81 million and sales of obesity intervention products, including the Lap-Band system, ballooned 50% to $74 million. Overall, the diversified device and drug maker reported fourth quarter sales of $1.07 billion, up 31.7% from the same quarter a year ago. "While we obviously cannot fully predict future economic trends and their impact on our markets, up to today we have not detected any impact on our sales of any slowdown in consumer spending in the United States or other major markets in the world," CEO David Pyott noted. For 2008, the company forecasts device sales of $870 million-$955 million, up 12%-23% from $774 million in 2007, including facial aesthetics sales of $225 million-$255 million; breast implant sales of $330 million-$350 million; and obesity intervention sales of $315 million-$350 million
You may also be interested in...
BD’s TriPath Imaging Buyout Would Integrate Cancer Diagnostics Partner
Becton Dickinson will gain TriPath Imaging's SurePath liquid-based Pap test and fledgling molecular oncology diagnostics business should its $350 mil. acquisition offer be accepted
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.